These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10422754)

  • 1. In vitro, ex vivo, in vivo veritas.
    Borgström L
    Allergy; 1999; 54 Suppl 49():88-92. PubMed ID: 10422754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products.
    Olsson B; Borgström L; Lundbäck H; Svensson M
    J Aerosol Med Pulm Drug Deliv; 2013 Dec; 26(6):355-69. PubMed ID: 23421897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lung deposition of budesonide from the novel dry powder inhaler Airmax.
    Hirst RH; Newman SR; Clark DA; Hertog MG
    Respir Med; 2002 Jun; 96(6):389-96. PubMed ID: 12117037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma.
    Bisgaard H; Klug B; Sumby BS; Burnell PK
    Eur Respir J; 1998 May; 11(5):1111-5. PubMed ID: 9648964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Respiratory deposition patterns of salbutamol pMDI with CFC and HFA-134a formulations in a human airway replica.
    Cheng YS; Fu CS; Yazzie D; Zhou Y
    J Aerosol Med; 2001; 14(2):255-66. PubMed ID: 11681657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aerosol particle generation from dry powder inhalers: can they equal pressurized metered dose inhalers?
    Olsson B
    J Aerosol Med; 1995 Sep; 8 Suppl 3():S13-8; discussion S19. PubMed ID: 10172642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variability of fine particle dose and lung deposition of budesonide delivered through two multidose dry powder inhalers.
    Munzel U; Marschall K; Fyrnys B; Wedel M
    Curr Med Res Opin; 2005 Jun; 21(6):827-33. PubMed ID: 15969882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma scintigraphic evaluation of a novel budesonide dry powder inhaler using a validated radiolabeling technique.
    Warren S; Taylor G; Smith J; Buck H; Parry-Billings M
    J Aerosol Med; 2002; 15(1):15-25. PubMed ID: 12006142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
    Pitcairn G; Reader S; Pavia D; Newman S
    J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scintigraphic comparison of budesonide deposition from two dry powder inhalers.
    Newman SP; Pitcairn GR; Hirst PH; Bacon RE; O'Keefe E; Reiners M; Hermann R
    Eur Respir J; 2000 Jul; 16(1):178-83. PubMed ID: 10933104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the primary particle size distributions of pressurized metered dose inhalers by using inkjet spray drying for targeting desired regions of the lungs.
    Ehtezazi T; Davies MJ; Seton L; Morgan MN; Ross S; Martin GD; Hutchings IM
    Drug Dev Ind Pharm; 2015 Feb; 41(2):279-91. PubMed ID: 24252108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical equivalence of budesonide dry powder inhaler and pressurized metered dose inhaler.
    Srichana T; Juthong S; Thawithong E; Supaiboonpipat S; Soorapan S
    Clin Respir J; 2016 Jan; 10(1):74-82. PubMed ID: 25043636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H; Safioti G; Keegstra JR; Gopalan G
    Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deposition patterns with Turbuhaler.
    Borgström L
    J Aerosol Med; 1994; 7(Suppl 1):S49-53. PubMed ID: 10147081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adapting the Abbreviated Impactor Measurement (AIM) concept to make appropriate inhaler aerosol measurements to compare with clinical data: a scoping study with the "Alberta" idealized throat (AIT) inlet.
    Mitchell J; Copley M; Sizer Y; Russell T; Solomon D
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):188-97. PubMed ID: 22857270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Airmax: a multi-dose dry powder inhaler.
    Keating GM; Faulds D
    Drugs; 2002; 62(13):1887-95; discussion 1896-7. PubMed ID: 12215059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Exploration of Factors Affecting
    Ruzycki CA; Martin AR; Finlay WH
    J Aerosol Med Pulm Drug Deliv; 2019 Dec; 32(6):405-417. PubMed ID: 31418632
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug delivery from the Turbuhaler and Nebuhaler pressurized metered dose inhaler to various age groups of children with asthma.
    Agertoft L; Pedersen S; Nikander K
    J Aerosol Med; 1999; 12(3):161-9. PubMed ID: 10623332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In-vitro intra- and inter-inhaler flow rate-dependent dosage emission from a combination of budesonide and eformoterol in a dry powder inhaler.
    Tarsin W; Assi KH; Chrystyn H
    J Aerosol Med; 2004; 17(1):25-32. PubMed ID: 15120010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.